Tags : Domain Therapeutics

Domain Therapeutics Signs Research and License Agreement with Boehringer Ingelheim

Shots: Domain to receive upfront, milestones, and royalties on sales from Boehringer Ingelheim The focus of the agreement is to discover & develop GPCRs, using Domain’s DTect-All and bioSens-All technology to characterize compounds for Neuropsychiatric Diseases GPCRs are receptors present in CNS, activates by binding with stimulus or ligand and regulates the functions of brain […]Read More